{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:59:19Z","timestamp":1790535559570,"version":"4.1.0"},"reference-count":83,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To describe the mechanism, efficacy, and safety of novel agents that have reached phase 3 clinical trials for the treatment of biopsy\u2010proven nonalcoholic steatohepatitis (NASH). A literature search was conducted using the PRISMA guidelines of MEDLINE databases (1990 to October 2020) with the following MeSH terms:\u202fNASH, nonalcoholic liver disease, fatty liver, liver diseases, steatohepatitis, liver fibrosis; combined with obeticholic acid, FXR agonist, cenicriviroc, CCR5 receptor antagonist, elafibranor, PPAR, selonsertib, ASK\u20101 inhibitor, resmetirom, THR\u2010\u03b2 receptor, arachidyl amido cholanoic acid (Aramchol\u2122), and SCD\u20101 modulator. Results were verified via clinicaltrials.gov, Google Scholar, and Google. Articles were included if the medications of interest had ongoing or completed phase 3 trials in biopsy\u2010proven NASH with outcomes directly related to NASH resolution. Eleven studies were identified involving obeticholic acid (OCA), elafibranor, cenicriviroc, Aramchol, and resmetirom. Two agents have reported data from phase 3 trials: OCA and elafibranor. OCA demonstrated safety and efficacy in NASH with a primary end point of improvement or NASH resolution; a new drug approval has been submitted. Elafibranor failed to show efficacy in NASH in the preliminary report from the RESOLVE\u2010IT trial; however, the study is being extended to reassess outcomes. The remaining agents demonstrated positive results in phase 2b studies and have initiated phase 3 trials. With projections for increased prevalence of patients with NASH and the current lack of treatment options, novel agents with targeted mechanisms could potentially change the treatment landscape. The manufacturer of OCA is first to submit a new drug application for the treatment of NASH. These novel agents may fill a pharmacotherapy gap in patients with NASH and possibly prevent progression to advanced liver disease.<\/jats:p>","DOI":"10.1002\/phar.2489","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T11:51:00Z","timestamp":1607169060000},"page":"315-328","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-936X","authenticated-orcid":false,"given":"Erenie","family":"Guirguis","sequence":"first","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Grace","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bolson","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"DellaVecchia","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ruble","sequence":"additional","affiliation":[{"name":"Taneja College of Pharmacy University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1419"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443344"},{"key":"e_1_2_9_6_1","unstructured":"Overview | Non\u2010alcoholic fatty liver disease (NAFLD): assessment and management | Guidance | NICE.https:\/\/www.nice.org.uk\/guidance\/ng49. Accessed May 15 2020."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13857"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.01.147"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.005"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16173104"},{"issue":"4","key":"e_1_2_9_11_1","first-page":"511","article-title":"Epidemiology and natural history of non\u2010alcoholic steatohepatitis","volume":"13","author":"Argo CK","year":"2009","journal-title":"Nonalcoholic Steatohepatitis"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13856"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i30.3361"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2446-4"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01295.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-1-200501040-00110"},{"key":"e_1_2_9_20_1","article-title":"The questionable association of vitamin E supplementation and mortality\u2013inconsistent results of different meta\u2010analytic approaches","volume":"55","author":"Gerss J","year":"2009","journal-title":"Cell Mol Biol Noisy\u2013Gd Fr"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874609811104020158"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0167"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.06.017"},{"key":"e_1_2_9_24_1","unstructured":"Genfit.A Multicenter Randomized Double\u2010Blind Placebo\u2010Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis. clinicaltrials.gov;2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02704403. Accessed June 8 2020."},{"key":"e_1_2_9_25_1","unstructured":"Tobira Therapeutics Inc.AURORA: A Phase 3 Study to evaluate the efficacy and safety of cenicriviroc for the treatment of liver fibrosis in adult subjects with nonalcoholic steatohepatitis. clinicaltrials.gov;2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03028740. Accessed June 8 2020."},{"key":"e_1_2_9_26_1","unstructured":"Galmed Research and Development Ltd.A Phase 3\/4 Multinational Multicenter Double\u2010Blind Placebo\u2010Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) The ARMOR Study. clinicaltrials.gov; 2019.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04104321. Accessed June 8 2020."},{"key":"e_1_2_9_27_1","unstructured":"Madrigal Pharmaceuticals Inc.A Phase 3 Multinational Double\u2010Blind Randomized Placebo\u2010Controlled Study of MGL\u20103196 (Resmetirom) in Patients With Non\u2010Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and\/or Hepatic Decompensation. clinicaltrials.gov; 2019.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03900429. Accessed June 8 2020."},{"key":"e_1_2_9_28_1","unstructured":"Madrigal Pharmaceuticals Inc.A 52\u2010Week Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL\u20103196) in Patients With Non\u2010Alcoholic Fatty Liver Disease (NAFLD) (MAESTRO\u2010NAFLD\u20101). clinicaltrials.gov;2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04197479. Accessed June 8 2020."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_9_30_1","volume-title":"Harper\u2019s Illustrated Biochemistry","author":"Botham KM","year":"2016"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122082"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.07.003"},{"key":"e_1_2_9_33_1","unstructured":"DailyMed \u2010 OCALIVA\u2010 obeticholic acid tablet film coated.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=cdfbe0cd\u2010eb15\u201045a1\u2010ac17\u2010531bcda21aec. Accessed May 15 2020."},{"key":"e_1_2_9_34_1","volume-title":"LiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury","year":"2012"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25327"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2012"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114548027"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2016.11.009"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.12.028"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.57"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.4103\/2231-4040.90879"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2007.03.002"},{"key":"e_1_2_9_43_1","unstructured":"DailyMed \u2010 INDOMETHACIN\u2010 indomethacin capsule.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1e65948c\u2010489c\u20104a32\u201065ce\u201060441fb23dd9. Accessed October 9 2020."},{"key":"e_1_2_9_44_1","unstructured":"Genfit.Phase 1 Open\u2010Label Study in Healthy Male Volunteers to evaluate the potential effect of Indomethacin on the Pharmacokinetics Parameters of Elafibranor. clinicaltrials.gov;2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT039.85969. Accessed October 8 2020."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4584-4591.2005"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0509703"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/7355_2014_40"},{"key":"e_1_2_9_48_1","unstructured":"AIDSinfo May 10 2013.A clinical overview of Cenicriviroc.https:\/\/www.thebodypro.com\/article\/a\u2010clinical\u2010overview\u2010of\u2010cenicriviroc. Accessed October 9 2020"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318213c2c0"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.038"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1107"},{"key":"e_1_2_9_52_1","unstructured":"Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers\u2010 Full Text View \u2010 ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03760848. Accessed October 9 2020."},{"key":"e_1_2_9_53_1","unstructured":"Galmed Research and Development Ltd.A Phase 1 Open\u2010Label Study to evaluate the safety tolerability and pharmacokinetics of aramchol in subjects with hepatic impairment. clinicaltrials.gov;2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04480827. Accessed October 8 2020."},{"key":"e_1_2_9_54_1","unstructured":"Aramchol has been used in trials studying the treatment of HIV Gallstones Fatty Liver Metabolic Syndrome and Nonalcoholic Steatohepatitis among others.https:\/\/go.drugbank.com\/drugs\/DB11860. Accessed October 9 2020."},{"key":"e_1_2_9_55_1","unstructured":"PubChem.Aramchol | C44H79NO5 | CID 18738120 \u2010 structure chemical names physical and chemical properties classification patents literature biological activities safety\/hazards\/toxicity information supplier lists and more.https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/18738120. Accessed May 15 2020."},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4019299"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0664"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1302"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.76.897.424"},{"issue":"5","key":"e_1_2_9_60_1","first-page":"337","article-title":"Hepatic dysfunction in hyperthyroidism","volume":"7","author":"Khemichian S","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14209"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.042"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"e_1_2_9_64_1","unstructured":"Intercept Pharmaceuticals.A Phase 3 Double\u2010Blind Randomized Long\u2010Term Placebo\u2010Controlled Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis. clinicaltrials.gov;2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548351. Accessed June 8 2020."},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0093"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"e_1_2_9_68_1","unstructured":"GENFIT.Announces Results from Interim Analysis of RESOLVE\u2010IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis | GENFIT.https:\/\/ir.genfit.com\/news\u2010releases\/news\u2010release\u2010details\/genfit\u2010announces\u2010results\u2010interim\u2010analysis\u2010resolve\u2010it\u2010phase\u20103\/. Accessed June 9 2020."},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2016.02.012"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31108"},{"key":"e_1_2_9_71_1","unstructured":"RatziuV deGuevaraL SafadiR et al.One\u2010year results of the Global Phase 2b randomized placebo\u2010 controlled ARREST Trial of Aramchol a Stearoyl CoA Desaturase modulator in NASH patients. 19.https:\/\/galmedpharma.com\/wpcontent\/uploads\/2018\/01\/Aramchol_Late\u2010Breaking_liver_meeting\u2010AASLD_2018.pdf. Accessed 3 February 2021."},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.07.056"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"e_1_2_9_74_1","unstructured":"American Liver Foundation.NASH Causes & Risk Factors.https:\/\/liverfoundation.org\/for\u2010patients\/about\u2010the\u2010liver\/diseases\u2010of\u2010the\u2010liver\/nonalcoholic\u2010steatohepatitis\u2010information\u2010center\/nash\u2010causes\u2010risk\u2010factors\/. Accessed June 9 2020."},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"e_1_2_9_76_1","unstructured":"National Diabetes Statistics Report | Data & Statistics | Diabetes | CDC. Published May 5 2020.https:\/\/www.cdc.gov\/diabetes\/data\/statistics\/statistics\u2010report.html. Accessed June 9 2020."},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071714"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.04.026"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020935105"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S158053"},{"issue":"2","key":"e_1_2_9_81_1","first-page":"240","article-title":"Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis","volume":"75","author":"Yilmaz Y","year":"2012","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_2_9_82_1","unstructured":"U.S. National Institute of Health U.S. National Library of Medicine. clinicaltrials.gov.https:\/\/clinicaltrials.gov\/ct2\/results?cond=nash&term=&cntry=&state=&city=&dist=. Accessed June 13 2020."},{"key":"e_1_2_9_83_1","unstructured":"FDA issues complete response letter for obeticholic acid for fibrosis due to NASH.https:\/\/www.healio.com\/news\/hepatology\/20200629\/fda\u2010issues\u2010complete\u2010response\u2010letter\u2010for\u2010obeticholic\u2010acid\u2010for\u2010fibrosis\u2010due\u2010to\u2010nash. Accessed November 19 2020."},{"key":"e_1_2_9_84_1","unstructured":"Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO\u2010NAFLD\u20101 a Second Phase 3 Multi\u2010Center Double\u2010Blind Randomized Placebo\u2010Controlled Study of Resmetirom (MGL\u20103196) in Patients With NASH and Presumed NASH. BioSpace.https:\/\/www.biospace.com\/article\/madrigal\u2010pharmaceuticals\u2010announces\u2010first\u2010patient\u2010dosed\u2010in\u2010maestro\u2010nafld\u20101\u2010a\u2010second\u2010phase\u20103\u2010multi\u2010center\u2010double\u2010blind\u2010randomized\u2010placebo\u2010controlled\u2010study\u2010of\u2010resmetirom\u2010mgl\u20103196\u2010in\u2010patients\u2010with\u2010nash\u2010and\u2010presumed\u2010nash\/. Accessed June 9 2020."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:54:07Z","timestamp":1761065647000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/phar.2489"],"URL":"https:\/\/doi.org\/10.1002\/phar.2489","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"2020-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}